Drugs for Glucose Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 144)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Insulin glargine |
Approved |
Phase 4 |
|
160337-95-1 |
118984454 |
Synonyms:
ABASAGLAR
ABASAGLAR KWIKPEN
ABASRIA
BASAGLAR
HOE-71GT
HOE-901
INS LANTUS
INS LANTUS OPTICLIK
INS LANTUS OPTISET
INS LANTUS SOLOSTAR
INSULIN GLARGINE
INSULIN GLARGINE (RDNA ORIGIN)
|
INSULIN GLARGINE RECOMBINANT
insulin glargine-yfgn
Insulina glargina
LANTUS
LANTUS (INSULIN GLARGINE [RDNA ORIGIN] INJECTION)
LANTUS SOLOSTAR
LY2963016
LY-2963016
MK-1293
TOUJEO
TOUJEO MAX SOLOSTAR
TOUJEO SOLOSTAR
|
|
2 |
|
Lopinavir |
Approved |
Phase 4 |
|
192725-17-0 |
92727 |
Synonyms:
378, ABT
A-157378.0
A-157378-0
ABT 378
ABT-378
ABT-378a-157378-0a-157378.0
Aluviran
Kaletra
|
Koletra
LOPINAVIR
LPV
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
SID124893167
SID144205757
SID50111692
|
|
3 |
|
Lamivudine |
Approved, Investigational |
Phase 4 |
|
134678-17-4 |
60825 |
Synonyms:
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-2'-Deoxy-3'-thiacytidine
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
3TC
3'-Thia-2',3'-dideoxycytidine
BCH 189
BCH 189, (-)-
BCH-189
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
b-L-2',3'-Dideoxy-3'-thiacytidine
b-L-3'-Thia-2',3'-dideoxycytidine
Epivir
|
EPIVIR-HBV
Epzicom
GR-109714X
Hepitec
HEPTOVIR
LAMIVUDIN
LAMIVUDINA
LAMIVUDINE
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-isomer
LAMIVUDINUM
ZEFFIX
Î’-L-2',3'-dideoxy-3'-thiacytidine
Î’-L-3'-thia-2',3'-dideoxycytidine
|
|
4 |
|
Zidovudine |
Approved |
Phase 4 |
|
30516-87-1 |
35370 |
Synonyms:
3' Azido 2',3' dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-dideoxythymidine
3'-Azido-3'-deoxythymidine
Antiviral azt
Apo-Zidovudine
Azidothymidine
AZT
AZT (antiviral)
AZT antiviral
AZT, antiviral
Aztec
BW a509U
BWA 509u
BWA509u
|
BWA-509u
BW-A509U
BW-A-509U
COMPOUND S
COMPOUND-S
Novo-Azt
NSC-602670
Retrovir
ZDV
Zidovudin
Zidovudina
Zidovudine
Zidovudine EP III
Zidovudinum
|
|
5 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 4 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
6 |
|
Pitavastatin |
Approved |
Phase 4 |
|
147511-69-1 |
5282452 |
Synonyms:
(e,3R,5S)-7-(2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-3,5-dihydroxyhept-6-enoic acid
Itavastatin
Itavastatin calcium
itavastatin|Livalo®
Livalo
Nisvastatin
NK 104
NK-104
|
NKS104
Pitavastatia
PITAVASTATIN
Pitavastatin calcium
Pitavastatin lactone
Pitavastatina
Pitavastatine
Pitavastatinum
|
|
7 |
|
Diazoxide |
Approved |
Phase 4 |
|
364-98-7 |
3019 |
Synonyms:
Diazossido
DIAZOXIDE
Diazoxido
Diazoxidum
Eudemine
EUDIMINE
Hyperstat
|
MUTABASE
NSC-64198
NSC-76130
Proglycem
Proglycem®|SCH-6783|SRG-95213
SCH-6783
SRG-95213
|
|
8 |
|
Atorvastatin |
Approved |
Phase 4 |
|
134523-00-5 |
60823 |
Synonyms:
(3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-(PROPAN-2-YL)-1H-PYRROL-1-YL]-3,5-DIHYDROXYHEPTANOIC ACID
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-FLUORO-phenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
ATORVASTATIN
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
Atorvastatina
Atorvastatine
Atorvastatinum
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
|
Cardyl
Faboxim
Hipolixan
Hydrate, atorvastatin calcium
LCF872
Lipitor
Lipitor®
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
Normalip
PREVENCOR
Sincol
Sortis
Sotis
TAHOR
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
Vastina
Xanator
Xarator
Xavator
ZARATOR
Zurinel
|
|
9 |
|
Iron |
Approved |
Phase 4 |
|
7439-89-6 |
29936 |
Synonyms:
Carbonyl iron
Eisen
Electrolytic iron
Fe
FE (III) ion
Fe(3+)
Fe(III)
fer
Ferric ion
Ferric iron
Ferrum
|
Ferrum metallicum
Hierro
Iron powder
Iron(3+)
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (fe(3+))
Iron, reduced
Reduced iron
|
|
10 |
|
Anti-Infective Agents |
|
Phase 4 |
|
|
|
11 |
|
Black Currant |
|
Phase 4 |
|
|
|
12 |
|
Antiviral Agents |
|
Phase 4 |
|
|
|
13 |
|
HIV Protease Inhibitors |
|
Phase 4 |
|
|
|
14 |
|
protease inhibitors |
|
Phase 4 |
|
|
|
Synonyms:
|
15 |
|
Anti-Retroviral Agents |
|
Phase 4 |
|
|
|
16 |
|
Lamivudine, zidovudine drug combination |
|
Phase 4 |
|
|
|
17 |
|
Anti-HIV Agents |
|
Phase 4 |
|
|
|
18 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 4 |
|
|
|
19 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 4 |
|
|
|
20 |
|
Reverse Transcriptase Inhibitors |
|
Phase 4 |
|
|
|
21 |
|
Antihypertensive Agents |
|
Phase 4 |
|
|
|
22 |
|
Vasodilator Agents |
|
Phase 4 |
|
|
|
23 |
|
Hormones |
|
Phase 4 |
|
|
|
24 |
|
Calcium, Dietary |
|
Phase 4 |
|
|
|
25 |
|
Pharmaceutical Solutions |
|
Phase 4 |
|
|
|
26 |
|
Calcium |
Nutraceutical |
Phase 4 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
27 |
|
Ramipril |
Approved |
Phase 3 |
|
87333-19-5 |
5362129 |
Synonyms:
(2S-(1(R*(r*)),2a,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate
(2S-(1(R*(r*)),2a,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
(2S-(1(R*(r*)),2α,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylate
(2S-(1(R*(r*)),2α,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
Acovil
Almirall brand OF ramipril
Altace
ALTACE (TN)
Altace®|HOE-498|Tritace®
Astra brand OF ramipril
AstraZeneca brand OF ramipril
Aventis brand OF ramipril
Aventis pharma brand OF ramipril
C09AA05
Carasel
Cardace
Delix
HOE 498
HOE-498
|
Hoechst brand OF ramipril
Hypren
Hytren
LOPACE
Lostapres
Monarch brand OF ramipril
Pramace
Promed brand OF ramipril
Quark
Ramace
RAMICOR
RAMIPRIL
Ramiprilum
Ramiprilum [Latin]
RANACE
Triatec
Tritace
Unipril
Vesdil
Zabien
|
|
28 |
|
Acarbose |
Approved, Investigational |
Phase 3 |
|
56180-94-0 |
441184 444254 |
Synonyms:
Acarbosa
Acarbose
Acarbosum
Bay g 5421
Bayer brand OF acarbose
BAY-G 5421
BAY-G 5421|BAY-G-5421|Glucobay®|Precose®
|
BAY-G-5421
Glucobay
Glucor
Glumida
Lasa brand OF acarbose
Prandase
Precose
|
|
29 |
|
Glucagon |
Approved |
Phase 3 |
|
16941-32-5 |
16133228 16186314 |
Synonyms:
[<sup>125</sup>I]-glucagon
GCG(53-81)
GLUCAGEN HYPOKIT
GLUCAGON
Glucagon (recombinant dna origin)
GLUCAGON EMERGENCY KIT
|
GLUCAGON RECOMBINANT
Glucagon, human
Glucagon, porcine
GLUCAGONE
GLUCAGONUM
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
|
|
30 |
|
Aluminum sulfate |
Approved |
Phase 3 |
|
10043-01-3 |
|
Synonyms:
Aluminium sulfate
Aluminium sulfate anhydrous
Aluminum sulfate anhydrous
|
Aluminum sulphate anhydrous
Dialuminum sulfate
Dialuminum trisulfate
|
|
31 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 3 |
|
21645-51-2 |
|
Synonyms:
Al(OH)3
Aldrox
Algeldrate
Algeldrate atlas brand
Algeldrate axcan brand
Algeldrate chefaro brand
Algeldrate roques brand
Algeldrate stiefel brand
Algeldrate whitehall brand
Algeldrate wyeth brand
Alhydrogel
ALterna gel
Alugel
Alumina, hydrated
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
Aluminiumhydroxid
Aluminum hydroxide
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Amphojel
|
Atlas brand OF algeldrate
Axcan brand OF algeldrate
Basalgel
Brasivil
chefaro Brand OF algeldrate
Dialume
Dried aluminium hydroxide
Dried aluminum hydroxide gel
Dried aluminum hydroxide gel fine granules
Hydrated alumina
Hydroxide, aluminum
Nephrox
Pepsamer
Rhône poulenc rorer brand OF algeldrate
Rhône-poulenc rorer brand OF algeldrate
Rocgel
Roques brand OF algeldrate
Sanofi winthrop brand OF algeldrate
SmithKline beecham brand OF algeldrate
Stiefel brand OF algeldrate
Whitehall brand OF algeldrate
Wyeth brand OF algeldrate
|
|
32 |
|
Tirzepatide |
Approved, Investigational |
Phase 3 |
|
2023788-19-2 |
156588324 |
Synonyms:
LY-3298176|LY3298176|Mounjaro®
|
|
|
33 |
|
Dulaglutide |
Approved, Investigational |
Phase 3 |
|
923950-08-7 |
|
Synonyms:
Dulaglutida
DULAGLUTIDE
LY2189265
|
|
|
34 |
|
Dapagliflozin |
Approved |
Phase 3 |
|
461432-26-8 |
9887712 |
Synonyms:
(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
BMS-512148
BMS-512148|Farxiga®|Forxiga®
BMS-512148-05
|
Dapagliflozin
Dapagliflozina
FARXIGA
FORXIGA
|
|
35 |
|
Metformin |
Approved |
Phase 3 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
36 |
|
Linagliptin |
Approved |
Phase 3 |
|
668270-12-0 |
57389748 10096344 |
Synonyms:
(R)-8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-YNYL-3-METHYL-1-(4-METHYLQUINAZOLIN-2-YLMETHYL)-3,7-DIHYDRO-PURINE-2,6-DIONE
BI 1356
BI-1356
BI-1356|Tradjenta®
BI-1356BS
BI-1356-BS
|
BS-1356-BS
LINAGLIPTIN
Linagliptina
TRADJENTA
TRAJENTA
|
|
37 |
|
Rosiglitazone |
Approved, Investigational |
Phase 3 |
|
122320-73-4, 155141-29-0 |
77999 |
Synonyms:
(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
5-((4-(2-(Methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
AVANDAMET
AVANDARYL
Avandia
Avandia®|rosiglizole
BRL-49653
BRL-49653C
BRL-49653-C
Gaudil
|
Glaxo wellcome brand OF rosiglitazone maleate
GlaxoSmithKline brand OF rosiglitazone maleate
Rosigliazone maleate
Rosiglitazon
Rosiglitazona
Rosiglitazone
Rosiglitazone maleate
Rosiglitazonum
Rosiglizole
SmithKline beecham brand OF rosiglitazone maleate
TDZ-01
|
|
38 |
|
Fenofibrate |
Approved |
Phase 3 |
|
49562-28-9 |
3339 |
Synonyms:
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoate 1-methylethyl ester
2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester
Abbott brand OF procetofen
ABT-335
ABT-335|Lipantil®|Supralip®|Tricor®
AbZ brand OF procetofen
Aliud brand OF procetofen
Ankebin
Antara
Antara micronized procetofen
Anto brand OF procetofen
Apo feno micro
Apo fenofibrate
Apo-fenofibrate
Apo-feno-micro
Apotex brand OF procetofen
AZU, fenofibrat
Azupharma brand OF procetofen
Betapharm brand OF procetofen
Bouchara brand OF procetofen
CiL
Controlip
CT Arzneimittel brand OF procetofen
CT-Arzneimittel brand OF procetofen
Debat, fénofibrate
Durafenat
Elasterate
Elasterin
Fenobeta
Fenobrate
Fenofanton
Fenofibrat abz
Fenofibrat al
Fenofibrat azu
Fenofibrat FPH
Fenofibrat heumann
Fenofibrat hexal
Fenofibrat ratiopharm
Fenofibrat stada
Fenofibrat von CT
FENOFIBRATE
Fénofibrate debat
Fénofibrate MSD
FENOFIBRATO
Fenofibrato [INN-Spanish]
Fenofibrat-ratiopharm
FENOFIBRATUM
Fenofibratum [INN-Latin]
Fenofibric acid
FENOGAL
FENOGLIDE
Fenotard
Finofibrate
Finofibric acid
FNF
Fournier brand OF procetofen
gate Brand OF procetofen
Gen fenofibrate
Gen-fenofibrate
Genpharm brand OF procetofen
GNR Pharma brand OF procetofen
GNR-Pharma brand OF procetofen
Heumann brand OF procetofen
Heumann, fenofibrat
Hexal brand OF procetofen
Hexal, fenofibrat
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionic acid
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
|
Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionic acid
Knoll brand OF procetofen
Lichtenstein brand OF procetofen
Lipanthyl
Lipantil
LIPANTIL (TN)
LIPANTIL MICRO 200
LIPANTIL MICRO 267
LIPANTIL MICRO 67
Liparison
Lipidex
Lipidil
Lipidil Micro
Lipidil Supra
Lipidil ter
Lipidil-ter
Lipifen
Lipirex
Lipoclar
Lipofen
Lipofene
Liposit
Lipsin
Livesan
Lofibra
Luxacor
Merck dura brand OF procetofen
Micronized procetofen, antara
MTW Brand OF procetofen
MTW Fenofibrat
MTW-Fenofibrat
Nolipax
Normalip
Novartis brand OF procetofen
Novo fenofibrate
Novo-fenofibrate
Novopharm brand OF procetofen
NSC-281319
Nu fenofibrate
Nu pharm brand OF procetofen
Nu-fenofibrate
Nu-pharm brand OF procetofen
Pharmascience brand OF procetofen
Phenofibrate
PMS Fenofibrate micro
PMS-Fenofibrate micro
Procetofen
Procetofen reliant brand
Procetofen, antara micronized
Procetofene
Proctofene
Protolipan
Q Pharm brand OF procetofen
Q-Pharm brand OF procetofen
Ratiopharm brand OF procetofen
Reliant brand OF procetofen
Schering plough brand OF procetofen
Schering-plough brand OF procetofen
Secalip
Sedufen
Stada, fenofibrat
Stadapharm brand OF procetofen
Supralip
SUPRALIP 160
Tricor
TRICOR (TN)
Triglide
Trilipix
United drug brand OF procetofen
|
|
39 |
|
Cholecalciferol |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
67-97-0, 1406-16-2 |
5280795 10883523 |
Synonyms:
(+)-Vitamin D3
(1S,3Z)-3-[(2E)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-1-CYCLOHEXANOL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-1-[(1R)-1,5-DIMETHYLHEXYL]-7A-METHYL-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENECYCLOHEXAN-1-OL
(1S,3Z)-3-[(2E)-2-[(1R,3AS,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-2,3,3A,5,6,7-HEXAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE]-4-METHYLIDENE-CYCLOHEXAN-1-OL
(1S,3Z)-3-{2-[(1R,4E,7AR)-7A-METHYL-1-[(2R)-6-METHYLHEPTAN-2-YL]-OCTAHYDRO-1H-INDEN-4-YLIDENE]ETHYLIDENE}-4-METHYLIDENECYCLOHEXAN-1-OL
(3 beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3BETA,Z,7E)-9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
(3Î’,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
(5Z,7E)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
3-BETA,Z,7E-9,10-SECOCHOLESTR-5,7,10(19)-TRIEN-3-OL
7-DEHYDROCHOLESTEROL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-BETA-OL
9,10-SECOCHOLESTA-5,7,10(19)-TRIEN-3-OL
9,10-SECOCHOLESTA-5,7,10-TRIEN-3-OL
ACCRETE D3
ACIFEROL D3
ACTIVATED
Activated 7-dehydrocholesterol
ADCAL-D3
ARACHITOL
AVITICOL
BIOLIFE VITAMIN D3
BIO-VITAMIN D3
CACIT D3
CALCEOS
CALCICHEW D3
CALCICHEW D3 FTE
CALCICHEW D3 ONCE DAILY
CALCI-D
Calciferol
Calciol
CALDRINK D3
CALFOVIT D3
CC
Cholecalciferol
CHOLECALCIFEROL D3
Cholecalciferols
Cholecalciferolum
COLECAL D3
Colecalciferol
Colecalciferolum
COLEKAL-D3
COLEVIT D3
CUBICOLE D3
D3 LEMON MELTS
D3-50
D3-VIGANTOL
DEKRISTOL
DELSTEROL
Delta-D
DEPARAL
DESUNIN
DEVARON
Dihydrocholesterol
DLUX 400
D-MAX
D-TRACETTEN
|
D-VIT3
EBIVIT
E-D3
EVACAL D3
FERACOL
FULTIUM DAILY D3
FULTIUM-D3
GRANUVIT D3
HUX D3
INVITA D3
ISO D3
KORA LIQUID
MICRO-DEE
NATECAL D3
NATURE'S REMEDY VITAMIN D3
NEO-D
NPHD3
NSC-375571
Oleovitamin D3
OSTEOCAPS D3
PLENACHOL
PRO D3
PRO D3 FOLIC
PRO D3 FORTE
PROVITINA
QUINTOX
RICKETON
ROYALVIT D3
STEXEROL-D3
STIVIT-D3
SUNVIT-D3 1,000
SUNVIT-D3 10,000
SUNVIT-D3 2,000
SUNVIT-D3 20,000
SUNVIT-D3 3,000
SUNVIT-D3 400
SUNVIT-D3 5,000
SUNVIT-D3 50,000
SUNVIT-D3 800
SYNERVIT-D3
THEICAL D-3
THORENS
TRIVITAN
VIDDE-3-HYDROSOL
VI-DE3
VIDEKHOL
VIGANTOL
VIGANTOLETTEN
VIGANTOLETTEN 500
VIGORSAN
VIT D3 STREULI
VITA-D3
VITAMIN D
Vitamin D 3
VITAMIN D ASSAY SYSTEM SUITABILITY
Vitamin D NOS
Vitamin D, unspecified form
Vitamin D3
Vitamin D-3
VITINC DAN-DEE-3
ZYMAD
δ-D
|
|
40 |
|
Glutamic acid |
Approved, Nutraceutical |
Phase 3 |
|
56-86-0 |
33032 |
Synonyms:
(+)-Estrone
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-b-D-Glucopyranosyl-b-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-beta-D-Glucopyranosyl-beta-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoate
(1S)-2-[(3-O-Β-D-glucopyranosyl-β-D-galactopyranosyl)oxy]-1-{[(9E)-octadec-9-enoyloxy]methyl}ethyl (10E)-nonadec-10-enoic acid
(2R)-2,3-Dihydroxypropanoic acid
(2S)-2-Aminopentanedioate
(2S)-2-Aminopentanedioic acid
(3R,4S,5R)-5-[(1R)-1-Carboxy-2,2-difluoro-1-(phosphonooxy)ethoxy]-4-hydroxy-3-(phosphonooxy)cyclohex-1-ene-1-carboxylate
(R)-2,3-Dihydroxypropanoic acid
(R)-Glycerate
(R)-Glyceric acid
(S)-(+)-Glutamate
(S)-(+)-Glutamic acid
(S)-2-Aminopentanedioate
(S)-2-Aminopentanedioic acid
(S)-Glutamate
(S)-Glutamic acid
1,3,5(10)-Estratrien-3-ol-17-one
1-Amino-2-hydroxyethane
1-Aminopropane-1,3-dicarboxylate
1-Amino-propane-1,3-dicarboxylate
1-Aminopropane-1,3-dicarboxylic acid
1-Amino-propane-1,3-dicarboxylic acid
2 Acetamido 2 deoxy D glucose
2 Acetamido 2 deoxyglucose
2 Aminoethanol
2-Acetamido-2-deoxy-D-glucose
2-Acetamido-2-deoxyglucose
2-Amino-1-ethanol
2-Aminoethan-1-ol
2-Aminoethanol
2-Amino-ethanol
2-Aminoethyl alcohol
2-Aminoglutarate
2-Aminoglutaric acid
2-Aminopentanedioate
2-Aminopentanedioic acid
2-Ethanolamine
2-Hydroxyethanamine
2-Hydroxyethylamine
3a,7a,12a-Trihydroxy-5b-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholan-24-oylglycine
3alpha,7alpha,12alpha-Trihydroxy-5beta-cholanic acid-24-glycine
3alpha,7alpha,12alpha-Trihydroxy-N-(carboxymethyl)-5beta-cholan-24-amide
3-Hydroxy-1,3,5(10)-estratrien-17-one
3-Hydroxy-17-keto-estra-1,3,5-triene
3-Hydroxyestra-1,3,5(10)-trien-17-one
3-Hydroxyestra-1,3,5(10)-triene-17-one
3-Hydroxyoestra-1,3,5(10)-trien-17-one
3Α,7α,12α-trihydroxy-5β-cholan-24-oylglycine
3Α,7α,12α-trihydroxy-5β-cholanic acid-24-glycine
3Α,7α,12α-trihydroxy-N-(carboxymethyl)-5β-cholan-24-amide
a,b-Hydroxypropionate
a,b-Hydroxypropionic acid
a-Aminoglutarate
a-Aminoglutaric acid
Acetylglucosamine
Acide glutamique
Acido glutamico
ácido glutámico
Acidum glutamicum
Aciglut
Aethanolamin
a-Glutamate
a-Glutamic acid
alpha,beta-Hydroxypropionate
alpha,beta-Hydroxypropionic acid
alpha-Aminoglutarate
alpha-Aminoglutaric acid
alpha-Glutamate
alpha-Glutamic acid
Aluminum L glutamate
Aluminum L-glutamate
Aminoethanol
Aminoglutarate
Aminoglutaric acid
b-Aminoethanol
b-Aminoethyl alcohol
beta-Aminoethanol
beta-Aminoethyl alcohol
beta-Ethanolamine
beta-Hydroxyethylamine
b-Ethanolamine
b-Hydroxyethylamine
Cholylglycine
Colamine
D Glutamate
D1,3,5(10)-Estratrien-3-ol-17-one
D-2,3-Dihydroxypropanoic acid
D-GlcNAc
D-Glutamate
|
D-Glycerate
D-Glyceric acid
D-GroA
E
E 620
E620
E-620
Envision conditioner PDD 9020
Estrone, (+-)-isomer
Estrone, (8 alpha)-isomer
Estrone, (9 beta)-isomer
Estrovarin
ETA
Ethylolamine
FEMA NO. 3285
Follicular hormone
Folliculin
Glt
Glu
Glusate
Glut
Glutacid
Glutamate
Glutamate, potassium
GLUTAMIC ACID
Glutamic acid, (D)-isomer
Glutamicol
Glutamidex
Glutaminate
Glutaminic acid
Glutaminol
Glutaton
Glycerate
Glycine cholate
Glycinol
Glycocholate
Glycocholate sodium
Glycocholic acid, sodium salt
Glycoreductodehydrocholic acid
Glycylcholate
Glycylcholic acid
Hauck brand OF estrone
Hea
H-Glycinol
Hyrex brand OF estrone
INS NO.620
INS-620
Kestrone
L Glutamate
L Glutamic acid
L-(+)-Glutamate
L-(+)-Glutamic acid
L-a-Aminoglutarate
L-a-Aminoglutaric acid
L-alpha-Aminoglutarate
L-alpha-Aminoglutaric acid
L-Glu
L-Glu|L-glutamate|poly-L-glutamate
L-GLUTAMATE
L-Glutamate, aluminum
L-GLUTAMIC ACID
L-Glutaminate
L-Glutaminic acid
L-Glutaminsaeure
MEA
Monoaethanolamin
MONOETHANOLAMINE
N Acetyl D glucosamine
N-(Carboxymethyl)-3alpha,7alpha,12alpha-trihydroxy-5beta-cholan-24-amide
N-(Carboxymethyl)-3α,7α,12α-trihydroxy-5β-cholan-24-amide
N-[(3a,5b,7a,12a)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3alpha,5beta,7alpha,12alpha)-3,7,12-Trihydroxy-24-oxocholan-24-yl]glycine
N-[(3Α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]glycine
N-Acetylchitosamine
N-Acetyl-D-glucosamine
N-Choloylglycine
N-Choloyl-glycine
NSC-143503
Oestrone
Olamine
Potassium glutamate
R-Glycerate
R-Glyceric acid
Unigen
Vortech brand OF estrone
Wehgen
Α,β-hydroxypropionate
Α,β-hydroxypropionic acid
Î’-aminoethanol
Î’-aminoethyl alcohol
Î’-ethanolamine
Î’-hydroxyethylamine
|
|
41 |
|
L-Glutamine |
Approved, Investigational, Nutraceutical |
Phase 3 |
|
56-85-9 |
5961 |
Synonyms:
(2S)-2,5-Diamino-5-oxopentanoate
(2S)-2,5-DIAMINO-5-OXOPENTANOIC ACID
(2S)-2-Amino-4-carbamoylbutanoate
(2S)-2-AMINO-4-CARBAMOYLBUTANOIC ACID
(S)-2,5-Diamino-5-oxopentanoate
(S)-2,5-DIAMINO-5-OXOPENTANOIC ACID
[<sup>14</sup>C]-glutamine
[<sup>3</sup>H]-glutamine
2-Aminoglutaramic acid
Cebrogen
D Glutamine
D-Glutamine
ENDARI
FEMA NO. 3684
gamma-Glutamine
Glavamin
GLN
Glumin
Glutamate 5-amide
Glutamate amide
GLUTAMIC ACID 5-AMIDE
GLUTAMIC ACID AMIDE
Glutamina
GLUTAMINE
L Glutamine
L-(+)-GLUTAMINE
|
L-2-Aminoglutaramate
L-2-AMINOGLUTARAMIC ACID
L-2-Aminoglutaramidic acid
Levoglutamid
Levoglutamida
LEVOGLUTAMIDE
Levoglutamidum
Levoglutamina
L-Glutamate g-amide
L-Glutamate gamma-amide
L-Glutamate γ-amide
L-Glutamic acid 5-amide
L-Glutamic acid g-amide
L-GLUTAMIC ACID GAMMA-AMIDE
L-GLUTAMIC ACID Γ-AMIDE
L-Glutamid
L-Glutamide
L-GLUTAMIN
L-GLUTAMINE
L-GLUTAMINSAEURE-5-AMID
L-GLUTAMINSÄURE-5-AMID
NSC-27421
NUTRESTORE
Polyglutamine
Q
Stimulina
|
|
42 |
|
Gastric inhibitory polypeptide |
Investigational |
Phase 3 |
|
100040-31-1 |
|
Synonyms:
GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE
|
|
|
43 |
|
2,4-thiazolidinedione |
Investigational |
Phase 3 |
|
2295-31-0 |
5437 |
Synonyms:
2,4(3H,5H)-Thiazoledione
2,4-Dioxothiazolidine
2,4-Thiazolidinedione
|
2,4-Thiazolidinedione potassium
THIAZOLIDINE-2,4-DIONE
Thiazolidinedione
|
|
44 |
|
Angiotensin-Converting Enzyme Inhibitors |
|
Phase 3 |
|
|
|
45 |
|
Trace Elements |
|
Phase 3 |
|
|
|
46 |
|
Micronutrients |
|
Phase 3 |
|
|
|
47 |
|
Glucagon-Like Peptide 1 |
|
Phase 3 |
|
|
|
48 |
|
Adjuvants, Immunologic |
|
Phase 3 |
|
|
|
49 |
|
Calciferol |
|
Phase 3 |
|
|
|
50 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 185)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Exploring the Association Between Phthalates Exposure, Measured Through Their Urinary Metabolites, and Renal Function Impairment in Individuals With TYpe 2 Diabetes - SGLT2 Subprotocol |
Unknown status |
NCT04242758 |
Phase 4 |
Dapagliflozin 10 MG;Hydrochlorothiazide 12.5mg |
2 |
Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study |
Completed |
NCT02689765 |
Phase 4 |
|
3 |
One-Year Glargine-Treatment Can Ameliorate Clinical Features in Cystic Fibrosis Children and Adolescents With Glucose Derangements |
Completed |
NCT00483769 |
Phase 4 |
Glargine |
4 |
A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism |
Completed |
NCT00192621 |
Phase 4 |
Combivir (zidovudine [AZT] / lamivudine [3TC]);Kaletra (lopinavir [LPVr]) |
5 |
Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance |
Completed |
NCT00108615 |
Phase 4 |
Metformin;Pioglitazone |
6 |
Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in Acute Myocardial Infarction (AMI) Patients With Abnormal Glucose Metabolism: a Multicenter Prospective Randomized Clinical Trial |
Recruiting |
NCT04945122 |
Phase 4 |
Pitavastatin;Atorvastatin |
7 |
Comparison of Oral Semaglutide With Matched Oral Semaglutide Placebo as an Early Treatment for Latino Adults With Type 2 Diabetes Receiving Enhanced Lifestyle Care |
Recruiting |
NCT04938388 |
Phase 4 |
Semaglutide Pill |
8 |
The Impact of Different Initial Insulin Dose Regimens on Time to Achieve Glycemic Targets and Treatment Safety in Short-term Intensive Insulin Therapy(SIIT) |
Recruiting |
NCT05084079 |
Phase 4 |
CSII with formula-based initial insulin regimen;CSII with weight-based initial insulin regimen |
9 |
Central Mechanisms That Regulate Glucose Metabolism in Humans |
Active, not recruiting |
NCT01028846 |
Phase 4 |
Diazoxide;Placebo |
10 |
A 24-week, Multi-center, Randomized, Open-Label Clinical Trial to Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes (XTREME Study) |
Not yet recruiting |
NCT05238012 |
Phase 4 |
Xuezhikang Capsule;Atorvastatin Calcium Tablets |
11 |
A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age. |
Terminated |
NCT03191201 |
Phase 4 |
Ferric Carboxymaltose;0.9% sodium chloride solution |
12 |
Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance |
Withdrawn |
NCT00306826 |
Phase 4 |
pioglitazone;simvastatin;pioglitazone + simvastatin |
13 |
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial |
Completed |
NCT00095654 |
Phase 3 |
Ramipril;Rosiglitazone |
14 |
Effects of Acarbose Long-Term Therapy on Prevention of Cardiovascular Events in Abnormal Glucose Tolerance With Coronary Artery Disease (ALERT Study) |
Completed |
NCT00221156 |
Phase 3 |
Acarbose |
15 |
A Randomized, Double-blind Study Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Metformin Alone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia Not Appropriately Controlled With a Statin. |
Completed |
NCT00362323 |
Phase 3 |
fenofibrate (F) + metformin (M) hydrochloride fixed combination;Metformin |
16 |
A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Low and Standard Doses of Fenofibrate in Combination With Metformin on the Lipid Profile in Patients With Type 2 Diabetes and Dyslipidemia. |
Completed |
NCT00349128 |
Phase 2, Phase 3 |
fenofibrate and metformin combination (drug) |
17 |
An Open Label, Parallel-Arm, Multicenter Trial Assessing the Acceptability of 4 Dosages of a New Fixed Dose Combination of Fenofibrate and Metformin in Patients With Type 2 Diabetes and Dyslipidemia |
Completed |
NCT00348725 |
Phase 3 |
fenofibrate and metformin fixed combination (drug) |
18 |
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both |
Recruiting |
NCT05260021 |
Phase 3 |
Tirzepatide Dose 1;Tirzepatide Dose 2;Placebo |
19 |
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Diamyd® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype |
Recruiting |
NCT05018585 |
Phase 3 |
|
20 |
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN) |
Active, not recruiting |
NCT04809220 |
Phase 3 |
Dulaglutide;Biguanide (BG);Sulfonylurea (SU);Alpha-Glucosidase Inhibitors (α-GI);Thiazolidinedione (TZD);Glinides (GLN);Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) |
21 |
A Multi-center, Randomized, Double-Blind, Active-controlled, Phase 3, Study to Evaluate the Efficacy and Safety of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on Metformin |
Not yet recruiting |
NCT05505994 |
Phase 3 |
DWP16001;Dapagliflozin;DWP16001 Placebo;Dapagliflozin Placebo |
22 |
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 |
Terminated |
NCT04371978 |
Phase 3 |
Linagliptin 5 MG |
23 |
Latinos Using Cardio Health Actions to Reduce Risk (LUCHAR): Effect of Omega-3 Fatty Acids on Vascular Function and Inflammation |
Terminated |
NCT00935766 |
Phase 3 |
Omega-3;Placebo |
24 |
A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of a Fixed Combination of Fenofibrate and Metformin vs Rosiglitazone in Patients With Type 2 Diabetes Mellitus and Dyslipidemia |
Terminated |
NCT00361868 |
Phase 3 |
fenofibrate (F) + metformin (M) hydrochloride fixed combination;Rosiglitazone |
25 |
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes |
Unknown status |
NCT03682640 |
Phase 2 |
Azithromycin Monohydrate;Insulin Lispro |
26 |
Efficacy and Safety of Transplantation of Autologous Stem Cells Into Pancreatic Artery, Combined With Immunomodulation for the Treatment of Type 1 Diabetes Mellitus |
Completed |
NCT02644759 |
Phase 1, Phase 2 |
|
27 |
Comparaison d'Une Nouvelle Technique de Mesure de l'insulinorésistance Par Scintigraphie Avec la Technique de référence : Utilisation du 6-DIG Comme Marqueur du Transport du Glucose. |
Completed |
NCT02102737 |
Phase 2 |
6-DIG |
28 |
Phase 1 Study of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes |
Completed |
NCT01935804 |
Phase 2 |
Pioglitazone;Metformin |
29 |
A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 Diabetes |
Completed |
NCT03345004 |
Phase 2 |
|
30 |
Acute Metabolic Effects of Melatonin Treatment |
Completed |
NCT03204877 |
Phase 1, Phase 2 |
Melatonin |
31 |
An Open-label, Three-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Overnight Closed-loop in Comparison With CGM Alone in the Home Setting in Children and Adolescents With Type 1 Diabetes |
Completed |
NCT01778348 |
Phase 2 |
|
32 |
Effect of Inhibition Soluble Epoxide Hydrolase on Insulin Sensitivity in Humans |
Completed |
NCT03486223 |
Phase 2 |
GSK2256294;Placebo oral capsule |
33 |
IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes |
Recruiting |
NCT04227769 |
Phase 2 |
Anakinra Prefilled Syringe |
34 |
Glucose Metabolism in South Asian Women With IGT or IFG. DIAbetes in South Asians - DIASA 3: A 12-week Intervention Trial With Oral Antidiabetic Medication to Improve Hepatic and Whole Body Insulin Sensitivity |
Recruiting |
NCT04662866 |
Phase 2 |
Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg |
35 |
OsteoPreP: The Effect of Probiotic Supplementation on Bone, Muscle, and Glucose Metabolism in Postmenopausal Women: A Randomised Placebo-controlled Trial |
Recruiting |
NCT05348694 |
Phase 1, Phase 2 |
|
36 |
Regulation of Endogenous Glucose Production by Central KATP Channels |
Recruiting |
NCT03540758 |
Phase 2 |
Diazoxide;Nicotinic acid;Placebo |
37 |
Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D) |
Active, not recruiting |
NCT03181399 |
Phase 2 |
Triheptanoin |
38 |
Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide |
Active, not recruiting |
NCT03566511 |
Phase 2 |
Diazoxide;Placebo |
39 |
An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D) |
Not yet recruiting |
NCT05565248 |
Phase 1, Phase 2 |
|
40 |
A Double-Blind, Placebo-Controlled, Cross-over Trial, Evaluating Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults |
Not yet recruiting |
NCT04824872 |
Phase 2 |
Dasiglucagon;Placebo |
41 |
The Role of Hepatic Denervation in the Dysregulation of Glucose Metabolism in Liver Transplant Recipients |
Suspended |
NCT03685773 |
Phase 2 |
Diazoxide;Placebo (for diazoxide);Nicotinic acid |
42 |
Metabolic Effects of Melatonin Treatment |
Completed |
NCT03859934 |
Phase 1 |
Melatonin;Placebo Oral Tablet |
43 |
Aldosterone and the Metabolic Syndrome: Renin Inhibition Versus Mineralocorticoid Receptor (MR) Antagonism |
Completed |
NCT01103245 |
Phase 1 |
Hydrochlorothiazide (HCTZ);Aliskiren 150 mg (ALI 150);Spironolactone (SPL 25);Aliskiren 300 mg (ALI 300);Spironolactone 50 mg (SPL 50) |
44 |
A Phase 1 Placebo-Controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Food Effect of Single Escalating Oral Doses of PF-04991532 in Healthy Adult Subjects |
Completed |
NCT01102673 |
Phase 1 |
PF-04991532;Placebo |
45 |
A Phase 1 Placebo-Controlled Trial to Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses of PF-04991532 in Adult Patients With Type 2 Diabetes Mellitus (T2DM) |
Completed |
NCT01129258 |
Phase 1 |
PF-04991532;Placebo |
46 |
A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Dose Escalation Study In Japanese Healthy Subjects, And Open Label, Single Dose Study In Western Healthy Subjects To Investigate The Safety, Tolerability, And Pharmacokinetics of PF-04991532. |
Completed |
NCT01369277 |
Phase 1 |
PF-04991532;Placebo |
47 |
A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 In Otherwise Healthy Overweight And Obese Subjects |
Completed |
NCT01757756 |
Phase 1 |
Pf-05175157;placebo;midazolam |
48 |
A Phase 1, Double-blind, Placebo-controlled, Randomized, Parallel Group Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04856883 In Adult Female Subjects With Type 2 Diabetes Mellitus |
Completed |
NCT01301456 |
Phase 1 |
|
49 |
An Open-Label, First-In-Human Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With Type 1 Diabetes Mellitus (T1D) |
Recruiting |
NCT05210530 |
Phase 1 |
|
50 |
Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial |
Active, not recruiting |
NCT03041363 |
Phase 1 |
Triheptanoin |
|